pioglitazone has been researched along with Diabetic Angiopathies in 80 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 9.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| " This study aims to assess the effect of pioglitazone on the vasculature of patients with impaired glucose tolerance (IGT)." | 9.14 | Effect of pioglitazone on endothelial function in impaired glucose tolerance. ( Hamilton, PK; Lockhart, CJ; Loughrey, CM; McVeigh, GE; Quinn, CE, 2010) |
| "Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure." | 9.12 | Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). ( Charbonnel, B; Dormandy, JA; Erdmann, E; Massi-Benedetti, M; Skene, AM; Spanheimer, R; Standl, E; Tan, M; Wilcox, RG; Yates, J, 2007) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 7.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy." | 5.33 | Pioglitazone initiation and subsequent hospitalization for congestive heart failure. ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 5.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| " This study aims to assess the effect of pioglitazone on the vasculature of patients with impaired glucose tolerance (IGT)." | 5.14 | Effect of pioglitazone on endothelial function in impaired glucose tolerance. ( Hamilton, PK; Lockhart, CJ; Loughrey, CM; McVeigh, GE; Quinn, CE, 2010) |
| " The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline." | 5.14 | Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure." | 5.12 | Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). ( Charbonnel, B; Dormandy, JA; Erdmann, E; Massi-Benedetti, M; Skene, AM; Spanheimer, R; Standl, E; Tan, M; Wilcox, RG; Yates, J, 2007) |
| "The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA(1c) levels and increased plasma adiponectin concentrations relative to the control group (P < 0." | 5.10 | Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. ( Kono, S; Kuzuya, H; Nakao, K; Ogawa, Y; Satoh, N; Shimatsu, A; Sugawara, A; Sugiyama, H; Tagami, T; Uesugi, H; Usui, T; Yamada, K, 2003) |
| "The goal of the meta-analysis was to evaluate the effect of pioglitazone on the primary and secondary prevention of cardiovascular diseases (CVDs) and renal adverse events in patients with or at high risk of type 2 diabetes mellitus (T2DM)." | 5.05 | Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. ( Huang, Y; Ji, X; Shen, L; Wang, X; Wang, Y; Zhou, Y, 2020) |
| "Pioglitazone has diverse multiple effects on metabolic and inflammatory processes that have the potential to influence cardiovascular disease pathophysiology at various points in the disease process, including atherogenesis, plaque inflammation, plaque rupture, haemostatic disturbances and microangiopathy." | 4.86 | Pioglitazone and mechanisms of CV protection. ( Erdmann, E; Wilcox, R, 2010) |
| " Available data suggest that pioglitazone can delay progression of atherosclerosis in patients with type 2 diabetes, as shown by the PERISCOPE and CHICAGO studies, and that it can reduce the rate of clinical CV events as shown by PROactive." | 4.85 | Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. ( Fisher, M, 2009) |
| "The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-gamma, and decreases metabolic and vascular insulin resistance." | 4.83 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. ( Forst, T; Pfützner, A; Schneider, CA, 2006) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 3.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Patients with type 2 diabetes face an increased risk of macrovascular disease compared to those without." | 3.82 | PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. ( Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R, 2007) |
| "To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism." | 3.80 | Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. ( Bai, SJ; Gao, X; Ye, XM; Zhang, J; Zhang, M, 2014) |
| "The present study demonstrated that pioglitazone can restore the nocturnal BP declines in parallel to reductions in the HOMA index, suggesting that insulin resistance may play an important role in the genesis of circadian BP rhythms." | 3.74 | Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. ( Anan, F; Eshima, N; Fukunaga, N; Iwao, T; Kaneda, K; Masaki, T; Okada, K; Saikawa, T; Teshima, Y; Umeno, Y; Wakasugi, K; Yonemochi, H; Yoshimatsu, H, 2007) |
| "Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow-up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design." | 2.82 | Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. ( Erdmann, E; Harding, S; Lam, H; Perez, A, 2016) |
| "The double-blind period bladder cancer imbalance did not persist in follow-up." | 2.79 | Observational follow-up of the PROactive study: a 6-year update. ( Erdmann, E; Perez, A; Song, E; Spanheimer, R; van Troostenburg de Bruyn, AR, 2014) |
| "Pioglitazone use in combination with insulin resulted in a sustained improved glycemic control and allowed the treatment regimens to be simplified and the insulin doses reduced." | 2.75 | Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). ( Birkeland, K; Charbonnel, B; Davidson, J; DeFronzo, R; Pirags, V; Scheen, A; Schmitz, O, 2010) |
| "The study included 15 subjects with type 2 diabetes with normoalbuminuria (age, 60." | 2.73 | Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. ( Kashiwagi, A; Maeda, K; Maegawa, H; Nakao, K; Nishio, Y; Ugi, S; Uzu, T, 2007) |
| "Thirty subjects with type 2 diabetes were initiated on intensive insulin therapy (continuous subcutaneous insulin infusion [n = 12] or multiple daily injections [n = 18]) and then randomized to either pioglitazone (PIO group;45 mg/day), ramipril (RAM group; 10 mg/day), or placebo (PLC group) for 36 weeks." | 2.73 | Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. ( Cersosimo, E; Cusi, K; DeFronzo, R; Fernandez, M; Musi, N; Sriwijilkamol, AA; Triplitt, C; Wajcberg, E, 2008) |
| "The treatment with pioglitazone in type 2 diabetic patients significantly reduced leptin." | 2.72 | A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. ( Fukui, T; Itoh, S; Katagiri, T; Kawamura, K; Konno, N; Kusuyama, T; Nishio, K; Sakurai, M; Shigemitsu, M, 2006) |
| "Pioglitazone treatment can convey direct protection against cytokine (TNF-alpha)-induced endothelial dysfunction in humans with an increased cardiovascular risk due to type 2 diabetes." | 2.72 | TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. ( de Koning, EJ; Martens, FM; op 't Roodt, J; Rabelink, TJ; Visseren, FL, 2006) |
| "Type 2 diabetes has long been recognized as an independent risk factor for cardiovascular disease (CVD), including coronary artery disease (CAD), stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure." | 2.47 | Macrovascular effects and safety issues of therapies for type 2 diabetes. ( Plutzky, J, 2011) |
| "Treatment with pioglitazone produced improvement in several parameters, such as systolic blood pressure and lipid levels, including a 14% increase in HDL cholesterol, and reduced CIMT progression, compared with glimepiride." | 2.45 | The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. ( Davidson, M; Mazzone, T; Polonsky, T, 2009) |
| "The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States." | 2.44 | PPARgamma agonists and coronary atherosclerosis. ( Chilton, R; Sulistio, MS; Thukral, N; Zion, A, 2008) |
| "Type 2 diabetes mellitus has become a true epidemic and significant growth is expected in the next decades." | 2.43 | [Pioglitazone. Review of its metabolic and systemic effects]. ( Cebrián Blanco, S; Durán García, S; Rodríguez Bernardino, A, 2005) |
| "Insulin resistance is associated with inflammation and has a key role in atherogenesis." | 2.43 | Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. ( Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R, 2006) |
| "Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy." | 2.43 | [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006) |
| "The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments." | 2.42 | Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004) |
| "Pioglitazone is a thiazolidinedione that increases insulin sensitivity in target tissues." | 2.41 | Pharmacokinetics and clinical efficacy of pioglitazone. ( Hanefeld, M, 2001) |
| "Patients with type 2 diabetes (T2DM) are at risk of long-term vascular complications." | 1.38 | Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. ( Alperin, P; Blickensderfer, A; Cohen, M; Gaebler, JA; Han, J; Hoogwerf, B; Maggs, D; Pencek, R; Peskin, B; Soto-Campos, G; Wintle, M, 2012) |
| "Incident myocardial infarction, congestive heart failure, and all cause mortality." | 1.35 | Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. ( Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR, 2009) |
| "This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy." | 1.33 | Pioglitazone initiation and subsequent hospitalization for congestive heart failure. ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005) |
| "Treatment with pioglitazone significantly improved glucose and lipid metabolism." | 1.30 | Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. ( Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.25) | 18.2507 |
| 2000's | 50 (62.50) | 29.6817 |
| 2010's | 27 (33.75) | 24.3611 |
| 2020's | 2 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Y | 1 |
| Huang, Y | 1 |
| Ji, X | 1 |
| Wang, X | 1 |
| Shen, L | 1 |
| Wang, Y | 1 |
| Yen, CL | 1 |
| Wu, CY | 1 |
| See, LC | 1 |
| Li, YJ | 1 |
| Tseng, MH | 1 |
| Peng, WS | 1 |
| Liu, JR | 1 |
| Chen, YC | 2 |
| Yen, TH | 1 |
| Tian, YC | 1 |
| Yang, CW | 1 |
| Anderson, GF | 1 |
| Yang, HY | 1 |
| Gao, H | 1 |
| Li, H | 1 |
| Li, W | 1 |
| Shen, X | 1 |
| Di, B | 1 |
| Patorno, E | 1 |
| Gopalakrishnan, C | 1 |
| Brodovicz, KG | 1 |
| Meyers, A | 1 |
| Bartels, DB | 1 |
| Liu, J | 2 |
| Kulldorff, M | 1 |
| Schneeweiss, S | 1 |
| Erdmann, E | 10 |
| Song, E | 1 |
| Spanheimer, R | 3 |
| van Troostenburg de Bruyn, AR | 1 |
| Perez, A | 2 |
| Nitta, Y | 2 |
| Tahara, N | 2 |
| Tahara, A | 2 |
| Honda, A | 1 |
| Kodama, N | 2 |
| Mizoguchi, M | 2 |
| Kaida, H | 2 |
| Ishibashi, M | 2 |
| Hayabuchi, N | 2 |
| Ikeda, H | 2 |
| Yamagishi, S | 2 |
| Imaizumi, T | 2 |
| Zhang, M | 1 |
| Gao, X | 1 |
| Bai, SJ | 1 |
| Ye, XM | 1 |
| Zhang, J | 1 |
| Heng, XP | 1 |
| Li, L | 1 |
| Huang, SP | 1 |
| Chen, Y | 1 |
| Lin, MX | 1 |
| Zhuang, HS | 1 |
| Yan, QF | 1 |
| Yang, LQ | 1 |
| Chen, L | 1 |
| Lin, Q | 1 |
| Cheng, XL | 1 |
| Chen, ML | 1 |
| Lan, YL | 1 |
| Wang, ZT | 1 |
| Yao, SH | 1 |
| Zhang, ZS | 1 |
| Hong, SJ | 1 |
| Choi, SC | 1 |
| Cho, JY | 1 |
| Joo, HJ | 1 |
| Park, JH | 1 |
| Yu, CW | 1 |
| Lim, DS | 1 |
| Shinke, T | 1 |
| Ryder, RE | 2 |
| Harding, S | 1 |
| Lam, H | 1 |
| DeFronzo, RA | 2 |
| Chilton, R | 2 |
| Norton, L | 1 |
| Clarke, G | 1 |
| Abdul-Ghani, M | 1 |
| Singh, S | 1 |
| Furberg, CD | 1 |
| Krentz, A | 1 |
| Barnett, AH | 1 |
| Polonsky, T | 1 |
| Mazzone, T | 1 |
| Davidson, M | 1 |
| Fisher, M | 1 |
| Lambley, RG | 1 |
| Vahdani, K | 2 |
| Konstantinidis, A | 1 |
| Booth, A | 1 |
| Kaku, K | 1 |
| Daida, H | 1 |
| Kashiwagi, A | 2 |
| Yamashina, A | 1 |
| Yamazaki, T | 1 |
| Momomura, S | 1 |
| Iwase, T | 1 |
| Yamasaki, Y | 1 |
| Nagatsuka, K | 1 |
| Kitagawa, K | 1 |
| Kawamori, R | 1 |
| Fukuda, M | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Wilcox, R | 2 |
| Tzoulaki, I | 1 |
| Molokhia, M | 1 |
| Curcin, V | 1 |
| Little, MP | 1 |
| Millett, CJ | 1 |
| Ng, A | 1 |
| Hughes, RI | 1 |
| Khunti, K | 1 |
| Wilkins, MR | 1 |
| Majeed, A | 1 |
| Elliott, P | 1 |
| Hanefeld, M | 2 |
| Schönauer, M | 1 |
| Forst, T | 2 |
| Charbonnel, B | 5 |
| DeFronzo, R | 3 |
| Davidson, J | 1 |
| Schmitz, O | 1 |
| Birkeland, K | 1 |
| Pirags, V | 1 |
| Scheen, A | 1 |
| Asakura, M | 1 |
| Kim, J | 1 |
| Asanuma, H | 1 |
| Kitakaze, M | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Quinn, CE | 1 |
| Lockhart, CJ | 1 |
| Hamilton, PK | 1 |
| Loughrey, CM | 1 |
| McVeigh, GE | 1 |
| Esposito, K | 1 |
| Maiorino, MI | 1 |
| Di Palo, C | 1 |
| Gicchino, M | 1 |
| Petrizzo, M | 1 |
| Bellastella, G | 1 |
| Saccomanno, F | 1 |
| Giugliano, D | 1 |
| Joya-Galeana, J | 1 |
| Fernandez, M | 2 |
| Cervera, A | 1 |
| Reyna, S | 1 |
| Ghosh, S | 1 |
| Triplitt, C | 2 |
| Musi, N | 2 |
| Cersosimo, E | 2 |
| Pfister, R | 1 |
| Cairns, R | 1 |
| Schneider, CA | 3 |
| Plutzky, J | 1 |
| Tawakol, A | 1 |
| Finn, AV | 1 |
| Oba, T | 1 |
| Mawatari, K | 1 |
| Yasukawa, H | 1 |
| Harada, H | 1 |
| Marwick, TH | 1 |
| Narula, J | 1 |
| Gaebler, JA | 1 |
| Soto-Campos, G | 1 |
| Alperin, P | 1 |
| Cohen, M | 1 |
| Blickensderfer, A | 1 |
| Wintle, M | 1 |
| Maggs, D | 1 |
| Hoogwerf, B | 1 |
| Han, J | 1 |
| Pencek, R | 1 |
| Peskin, B | 1 |
| Satoh, N | 1 |
| Ogawa, Y | 1 |
| Usui, T | 1 |
| Tagami, T | 1 |
| Kono, S | 1 |
| Uesugi, H | 1 |
| Sugiyama, H | 1 |
| Sugawara, A | 1 |
| Yamada, K | 1 |
| Shimatsu, A | 1 |
| Kuzuya, H | 1 |
| Nakao, K | 2 |
| Dormandy, J | 2 |
| Massi-Benedetti, M | 4 |
| Skene, A | 1 |
| Belcher, G | 1 |
| Lambert, C | 1 |
| Goh, KL | 1 |
| Edwards, G | 1 |
| Valbuena, M | 1 |
| Shah, M | 1 |
| Kolandaivelu, A | 1 |
| Fearon, WF | 1 |
| Cho, L | 1 |
| Lewis, BE | 1 |
| Steen, LH | 1 |
| Leya, FS | 1 |
| Karter, AJ | 1 |
| Ahmed, AT | 1 |
| Moffet, HH | 1 |
| Parker, MM | 1 |
| Smyth, SS | 1 |
| Jennings, JL | 1 |
| Freemantle, N | 1 |
| Aumiller, J | 1 |
| Nishio, K | 1 |
| Sakurai, M | 1 |
| Kusuyama, T | 1 |
| Shigemitsu, M | 1 |
| Fukui, T | 1 |
| Kawamura, K | 1 |
| Itoh, S | 1 |
| Konno, N | 1 |
| Katagiri, T | 1 |
| Pratley, RE | 1 |
| Rodríguez Bernardino, A | 1 |
| Cebrián Blanco, S | 1 |
| Durán García, S | 1 |
| Schmitz, OE | 1 |
| Brock, B | 1 |
| Rungby, J | 1 |
| Madsbad, S | 1 |
| Martens, FM | 1 |
| Rabelink, TJ | 1 |
| op 't Roodt, J | 1 |
| de Koning, EJ | 1 |
| Visseren, FL | 1 |
| Ríos-Vázquez, R | 1 |
| Marzoa-Rivas, R | 1 |
| Gil-Ortega, I | 1 |
| Kaski, JC | 1 |
| Pfützner, A | 1 |
| Tamura, H | 1 |
| Mokuno, H | 1 |
| Daita, H | 1 |
| Nitschmann, S | 1 |
| Ruiz, E | 1 |
| Redondo, S | 1 |
| Gordillo-Moscoso, A | 1 |
| Tejerina, T | 1 |
| Takebayashi, K | 1 |
| Suetsugu, M | 1 |
| Wakabayashi, S | 1 |
| Aso, Y | 1 |
| Inukai, T | 1 |
| Valentine, WJ | 1 |
| Bottomley, JM | 1 |
| Palmer, AJ | 1 |
| Brändle, M | 1 |
| Foos, V | 1 |
| Williams, R | 1 |
| Dormandy, JA | 2 |
| Yates, J | 3 |
| Tan, MH | 1 |
| Maegawa, H | 1 |
| Nishio, Y | 1 |
| Ugi, S | 1 |
| Maeda, K | 1 |
| Uzu, T | 1 |
| Wilcox, RG | 1 |
| Skene, AM | 1 |
| Tan, M | 1 |
| Standl, E | 1 |
| Anan, F | 1 |
| Masaki, T | 1 |
| Fukunaga, N | 1 |
| Teshima, Y | 1 |
| Iwao, T | 1 |
| Kaneda, K | 1 |
| Umeno, Y | 1 |
| Okada, K | 1 |
| Wakasugi, K | 1 |
| Yonemochi, H | 1 |
| Eshima, N | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Wajcberg, E | 1 |
| Sriwijilkamol, AA | 1 |
| Cusi, K | 1 |
| Ferrannini, E | 1 |
| Schernthaner, G | 1 |
| Stojanovska, L | 1 |
| Honisett, SY | 1 |
| Komesaroff, PA | 1 |
| Bourassa, MG | 1 |
| Berry, C | 1 |
| Sulistio, MS | 1 |
| Zion, A | 1 |
| Thukral, N | 1 |
| Yoshimoto, T | 1 |
| Naruse, M | 1 |
| Nishikawa, M | 1 |
| Naruse, K | 1 |
| Tanabe, A | 1 |
| Seki, T | 1 |
| Imaki, T | 1 |
| Demura, R | 1 |
| Aikawa, E | 1 |
| Demura, H | 1 |
| Brunetti, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| International Multicenter Trial on the Prognostic Value of Arterial 18F-FDG PET Imaging in Patients With History of Myocardial Infarction[NCT05138718] | 2,041 participants (Anticipated) | Observational [Patient Registry] | 2021-12-01 | Recruiting | |||
| An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.[NCT02678676] | 3,599 participants (Actual) | Observational [Patient Registry] | 2004-11-30 | Completed | |||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.[NCT01144338] | Phase 3 | 14,752 participants (Actual) | Interventional | 2010-06-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants with incidences of at least 1 malignancy was reported. All malignancies included adrenal, biliary, bladder, brain, breast, cervix, colon/rectal, gastric, hematological, hepatic, lung, mesothelioma, metastases, oesophageal, oropharyngeal, ovarian/uterine, pancreas, prostate, renal, skin and others. (NCT02678676)
Timeframe: Up to Year 10
| Intervention | percentage of participants (Number) |
|---|---|
| Pioglitazone | 12.9 |
| Placebo | 13.2 |
The composite macro-vascular event or death included all-cause mortality, non-fatal myocardial infarction, cardiac intervention, stroke, major leg amputation (above the ankle), bypass surgery or revascularization in the leg. The percentage of participants in the observational study population having first occurrence of macro-vascular event or death during the 10-year observational study period was analyzed. The data were analyzed using the Cox regression with respect to time to the first occurrence of macro-vascular event or death. (NCT02678676)
Timeframe: Up to Year 10
| Intervention | percentage of participants (Number) |
|---|---|
| Pioglitazone | 58 |
| Placebo | 60.3 |
20 reviews available for pioglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus, Type 2; | 2020 |
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2016 |
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; | 2009 |
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic An | 2009 |
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Carotid Arteries; Chicago; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2009 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diab | 2009 |
Pioglitazone and mechanisms of CV protection.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angi | 2010 |
[Glycemic control and cardiovascular benefit: What do we know today?].
Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2010 |
Macrovascular effects and safety issues of therapies for type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Pro | 2011 |
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl | 2004 |
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Randomi | 2005 |
[Pioglitazone. Review of its metabolic and systemic effects].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agen | 2005 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathie | 2006 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti | 2006 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic An | 2007 |
The anti-atherogenic effects of thiazolidinediones.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diab | 2007 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2008 |
Pharmacokinetics and clinical efficacy of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Risk Fa | 2001 |
Pioglitazone: the future.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Forecasting; Humans; Hyp | 2001 |
23 trials available for pioglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Observational follow-up of the PROactive study: a 6-year update.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2014 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; | 2013 |
Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis.
Topics: Aged; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperplasi | 2015 |
Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2016 |
Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
Topics: Adult; Aged; Asian People; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Bli | 2009 |
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Dia | 2010 |
Effect of pioglitazone on endothelial function in impaired glucose tolerance.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fe | 2010 |
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An | 2010 |
Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Topics: Adult; Aged; Body Mass Index; Cell Survival; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dia | 2011 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabet | 2011 |
A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2013 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive | 2011 |
Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.
Topics: Adiponectin; Arteriosclerosis; Blood Pressure; Body Mass Index; C-Reactive Protein; Diabetes Mellitu | 2003 |
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Topics: Adult; Cardiovascular Diseases; Demography; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female | 2004 |
A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.
Topics: Aged; Blood Pressure; Coronary Disease; Coronary Restenosis; Cytokines; Diabetes Mellitus, Type 2; D | 2006 |
[The place of Glitazones in the treatment of diabetes: after the PROactive study].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H | 2006 |
TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Humans | 2006 |
Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Age | 2007 |
Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.
Topics: Adiponectin; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2007 |
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Hear | 2007 |
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ang | 2008 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic An | 2007 |
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Femal | 2008 |
38 other studies available for pioglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Diabetes Mellit | 2020 |
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli | 2017 |
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans | 2019 |
Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab | 2014 |
[Effect of dangua recipe on glycolipid metabolism and VCAM-1 and its mRNA expression level in Apo E(-/-) mice with diabetes mellitus].
Topics: Animals; Apolipoproteins E; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Angiopathies; D | 2014 |
Pioglitazone revisited to illuminate contemporary vascular reparative therapy in the era of drug-eluting stents.
Topics: Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Age | 2015 |
Pioglitazone: reports of its death are greatly exaggerated - it is alive and ready to resume saving lives.
Topics: Animals; Carcinogens; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Observational Studies as T | 2015 |
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Piogli | 2009 |
Rosiglitazone and pioglitazone. Beware macular oedema.
Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular E | 2009 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
[Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Metabolic Syndrome; P | 2010 |
A consistency-adjusted alpha-adaptive strategy for sequential testing.
Topics: Algorithms; Biostatistics; Captopril; Clinical Trials as Topic; Data Interpretation, Statistical; Di | 2010 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, | 2011 |
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Topics: Aged; Biomarkers; Blood Glucose; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type | 2012 |
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans | 2002 |
[Early effect of therapy with pioglitazone. Vascular damage significantly reduced].
Topics: Arteriosclerosis; Carotid Stenosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic An | 2002 |
[Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Prognos | 2002 |
[Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
Topics: Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Thera | 2003 |
[Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; H | 2003 |
[Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Drug Therapy, Combination; Germany; | 2003 |
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; | 2004 |
Pioglitazone-induced heart failure despite normal left ventricular function.
Topics: Aged; Diabetes Mellitus; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; | 2004 |
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabe | 2005 |
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Hospi | 2005 |
PPARgamma agonists: a new strategy for antithrombotic therapy.
Topics: Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hyperglycemia; Hypoglycemic Agents; Pioglitazone | 2005 |
[New studies, new strategies, new guidelines: so that diabetic patients will live longer].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Germany; Glycated Hemoglo | 2005 |
[How does the PROactive Study change therapy of diabetes?].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agen | 2005 |
The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Thiazol | 2006 |
[Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2007 |
[New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
Topics: Cerebral Infarction; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hum | 2006 |
Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.
Topics: Activin Receptors; Activin Receptors, Type I; Aged; Anaplastic Lymphoma Kinase; Apoptosis; Atheroscl | 2007 |
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female | 2007 |
Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa | 2007 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Melli | 2008 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dia | 1997 |
[Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Surviva | 2001 |